Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: A rare case report


Erdur F. M. , Soyoral Y. U. , Emre H., Begenik H., Canbaz E. T. , Erkoc R.

CLINICAL BIOCHEMISTRY, vol.45, pp.162-164, 2012 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45
  • Publication Date: 2012
  • Doi Number: 10.1016/j.clinbiochem.2011.09.025
  • Journal Name: CLINICAL BIOCHEMISTRY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.162-164

Abstract

Objectives: Fenofibrate is a fibric acid derivative that is used alone or combination with statins in the treatment of hyperlipidemia. These drugs have potential risks, including rhabdomyolysis and acute renal failure. Despite reports of rhabdomyolysis with the use of fenofibrate alone or with statin-fibrate combinations, there have been no cases of rhabdomyolysis described when fenofibrate was used alone to treat patients with chronic renal failure owing to nephrotic syndrome.